NEW YORK, NY / ACCESSWIRE / January 31, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Green Dot Corporation (NYSE:GDOT)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/green-dot-corporation-loss-submission-form?prid=5386&wire=1
Lead Plaintiff Deadline: February 18, 2020
Class Period: May 9, 2018 to November 7, 2019
Allegations against GDOT include that: (1) Green Dot's strategy to attract "high-value" long-term customers was at the expense of "one and done" customers; (2) Green Dot's "one and done" customers represented a significant source of revenues in its legacy segment; (3) consequently, Green Dot's strategy was self-sabotaging; and (4) as a result of the foregoing, Defendants' statements about its business and operations were materially false and misleading at all relevant times.
Exelon Corporation (NYSE:EXC)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/exelon-corporation-loss-submission-form?prid=5386&wire=1
Lead Plaintiff Deadline: February 14, 2020
Class Period: February 9, 2019 to November 1, 2019
Allegations against EXC include that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.
Geron Corporation (NASDAQ:GERN)
If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5386&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/574800/SHAREHOLDER-ALERT-GDOT-EXC-GERN-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
